Effect of body weight and composition on efavirenz, atazanavir or darunavir concentration

Flegal, 2010, Prevalence and trends in obesity among US adults, 1999–2008, JAMA, 303, 235, 10.1001/jama.2009.2014 Caballero, 2005, A nutrition paradox – underweight and obesity in developing countries, New Engl J Med, 352, 1514, 10.1056/NEJMp048310 Andrade, 2012, Prevalence and characteristics associated with malnutrition at hospitalization among patients with acquired immunodeficiency syndrome in Brazil, PloS One, 7, e48717, 10.1371/journal.pone.0048717 Crum-Cianflone, 2010, Increasing rates of obesity among HIV-infected persons during the HIV epidemic, PloS One, 5, e10106, 10.1371/journal.pone.0010106 Hanley, 2010, Effect of obesity on the pharmacokinetics of drugs in humans, Clin Pharmacokinet, 49, 71, 10.2165/11318100-000000000-00000 Brill, 2012, Impact of obesity on drug metabolism and elimination in adults and children, Clin Pharmacokinet, 51, 277, 10.2165/11599410-000000000-00000 Pai, 2007, Antimicrobial dosing considerations in obese adult patients, Pharmacotherapy, 27, 1081, 10.1592/phco.27.8.1081 Kozal, 2009, Drug-resistant human immunodefiency virus, Clin Microbiol Infect, 15, 69, 10.1111/j.1469-0691.2008.02687.x de Roche, 2012, Efavirenz in an obese HIV-infected patient – a report and an in vitro–in vivo extrapolation model indicate risk of underdosing, Antivir ther, 17, 1381, 10.3851/IMP2107 De Clercq, 2009, Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV, Int J Antimicrob Agents, 33, 307, 10.1016/j.ijantimicag.2008.10.010 Adkins, 1998, Efavirenz, Drugs, 56, 1055, 10.2165/00003495-199856060-00014 McKeage, 2009, Darunavir: a review of its use in the management of HIV infection in adults, Drugs, 69, 477, 10.2165/00003495-200969040-00007 Croom, 2009, Atazanavir: a review of its use in the management of HIV-1 infection, Drugs, 69, 1107, 10.2165/00003495-200969080-00009 Fenton, 2007, Darunavir: in the treatment of HIV-1 infection, Drugs, 67, 2791, 10.2165/00003495-200767180-00010 Busti, 2004, Atazanavir for the treatment of human immunodeficiency virus infection, Pharmacotherapy, 24, 1732, 10.1592/phco.24.17.1732.52347 Fabbiani, 2009, Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice, J Antimicrob Chemother, 64, 109, 10.1093/jac/dkp132 http://www.tanita.eu/products/ [Accessed 25 october 2017]. Nunez, 1997, Bioimpedance analysis: evaluation of leg-to-leg system based on pressure contact footpad electrodes, Med Sci Sports Exerc, 29, 524, 10.1097/00005768-199704000-00015 Thompson, 2012, Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel, JAMA, 308, 387, 10.1001/jama.2012.7961 Recommandations du groupe d’experts, 2013 Stohr, 2008, Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication, Antivir Ther, 13, 675, 10.1177/135965350801300507 Poeta, 2011, Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals, J Antimicrob Chemother, 66, 2601, 10.1093/jac/dkr360 Sinxadi, 2015, Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in south Africa, Br J Clin Pharmacol, 80, 146, 10.1111/bcp.12590 Li, 2012, Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment, Pharmacogenomics, 13, 555, 10.2217/pgs.11.160 Mouly, 2002, Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans, Clin Pharmacol Ther, 72, 1, 10.1067/mcp.2002.124519 Haas, 2004, Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trials group study, AIDS, 18, 2391 Stohr, 2010, Factors influencing lopinavir and atazanavir plasma concentration, J Antimicrob Chemother, 65, 129, 10.1093/jac/dkp408 von Hentig, 2008, The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors, J Antimicrob chemother, 62, 579, 10.1093/jac/dkn204 Colombo, 2006, Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection, Antimicrob Agents Chemother, 50, 3801, 10.1128/AAC.00098-06 Le Tiec, 2005, Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir, Clin Pharmacokinet, 44, 1035, 10.2165/00003088-200544100-00003 Lumeng, 2011, Inflammatory links between obesity and metabolic disease, J Clin Invest, 121, 2111, 10.1172/JCI57132 Lashinger, 2014, Obesity and resistance to cancer chemotherapy: interacting roles of inflammation and metabolic dysregulation, Clin Pharmacol Ther, 96, 458, 10.1038/clpt.2014.136 Kakuda, 2012, Pharmacokinetics and pharmacodynamics of darunavir and etravirine in hiv-1-infected, treatment-experienced patients in the gender, race and clinical experience (GRACE) trial, AIDS Res Treat, 2012, 186987 Molto, 2013, Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients, Clin Pharmacokinet, 52, 543, 10.1007/s40262-013-0057-6 McGraw, 2012, Cytochrome P450 variations in different ethnic populations, Expert Opin Drug Metab Toxicol, 8, 371, 10.1517/17425255.2012.657626